GLP-1减肥药市场博弈:礼来领航突破、辉瑞折戟沉沙,创新战如何取胜?

21世纪经济报道
18 Apr

全球GLP-1(胰高血糖素样肽-1)减肥药市场正迎来新一轮格局重塑。4月17日,礼来公布了3期临床研究ACHIEVE-1的积极顶线结果,该研究评估了orforglipron对比安慰剂,在饮食控制和运动基础上血糖控制仍不佳的2型糖尿病患者中的安全性和有效性。据了解,Orforglipron是首个成功完成3期试验、对饮食或饮水不加以限制的口服小分子胰高血糖素样肽-1(GLP-1)受体激动剂。如果该药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10